Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Celsion Corporation to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on Monday, November 16, 2020

11/09/2020 | 08:30am EST

LAWRENCEVILLE, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the third quarter ended September 30, 2020 and provide an update on its development programs for GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system and ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin at 11:00 a.m. ET on Monday, November 16, 2020.

To participate in the call, interested parties may dial 1-800-367-2403 (Toll-Free/North America) or 1-334-777-6978 (International/Toll) and ask for the Celsion Corporation Third Quarter 2020 Earnings Call (Conference Code: 8337630) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at www.celsion.com. The call will be archived for replay on Monday, November 16, 2020 and will remain available until November 30, 2020. The replay can be accessed at 1-719-457-0820 or 1-888-203-1112 using Conference ID: 8337630. An audio replay of the call will also be available on the Company's website, www.celsion.com, for 90 days after 2:00 p.m. ET Monday, November 16, 2020.

About Celsion Corporation

Celsion is a fully integrated oncology company focused on developing a portfolio of innovative cancer treatments, including immunotherapies, DNA-based therapies and directed chemotherapies. The Company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer and ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. Celsion has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit: http://www.celsion.com. (CLSN-FIN).

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact                                                                 LHA Investor Relations
Jeffrey W. Church                                                                              Kim Sutton Golodetz
Executive Vice President & CFO                                                       212-838-3777
609-482-2455                                                                                     kgolodetz@lhai.com
jchurch@celsion.com

# # #

Primary Logo


© GlobeNewswire 2020
All news about CELSION CORPORATION
2020CELSION CORP : Change in Directors or Principal Officers (form 8-K)
AQ
2020DEADLINE TODAY : The Schall Law Firm Announces it is Investigating Claims Agains..
BU
2020CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
2020CELSION CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
2020CELSION CORPORATION : Reports Third Quarter 2020 Financial Results and Provides ..
AQ
2020Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides..
GL
2020CLSN SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Cor..
BU
2020CELSION CORPORATION : to Hold Third Quarter 2020 Financial Results and Business ..
AQ
2020Celsion Corporation to Hold Third Quarter 2020 Financial Results and Business..
GL
2020CELSION : ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Celsion Corporation Investors ..
BU
More news
Financials (USD)
Sales 2020 0,50 M - -
Net income 2020 -23,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,25x
Yield 2020 -
Capitalization 34,1 M 34,1 M -
Capi. / Sales 2020 68,2x
Capi. / Sales 2021 -
Nbr of Employees 29
Free-Float 98,8%
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 3,00 $
Last Close Price 0,91 $
Spread / Highest target 229%
Spread / Average Target 229%
Spread / Lowest Target 229%
EPS Revisions
Managers and Directors
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION28.13%34
GILEAD SCIENCES, INC.15.12%84 074
VERTEX PHARMACEUTICALS-1.87%60 305
REGENERON PHARMACEUTICALS10.51%56 349
WUXI APPTEC CO., LTD.6.43%53 987
BEIGENE, LTD.38.04%32 523